Literature DB >> 21840484

Coordinated regulation of polycomb group complexes through microRNAs in cancer.

Qi Cao1, Ram-Shankar Mani, Bushra Ateeq, Saravana M Dhanasekaran, Irfan A Asangani, John R Prensner, Jung H Kim, J Chad Brenner, Xiaojun Jing, Xuhong Cao, Rui Wang, Yong Li, Arun Dahiya, Lei Wang, Mithil Pandhi, Robert J Lonigro, Yi-Mi Wu, Scott A Tomlins, Nallasivam Palanisamy, Zhaohui Qin, Jindan Yu, Christopher A Maher, Sooryanarayana Varambally, Arul M Chinnaiyan.   

Abstract

Polycomb Repressive Complexes (PRC1 and PRC2)-mediated epigenetic regulation is critical for maintaining cellular homeostasis. Members of Polycomb Group (PcG) proteins including EZH2, a PRC2 component, are upregulated in various cancer types, implicating their role in tumorigenesis. Here, we have identified several microRNAs (miRNAs) that are repressed by EZH2. These miRNAs, in turn, regulate the expression of PRC1 proteins BMI1 and RING2. We found that ectopic overexpression of EZH2-regulated miRNAs attenuated cancer cell growth and invasiveness, and abrogated cancer stem cell properties. Importantly, expression analysis revealed an inverse correlation between miRNA and PRC protein levels in cell culture and prostate cancer tissues. Taken together, our data have uncovered a coordinate regulation of PRC1 and PRC2 activities that is mediated by miRNAs.
Copyright © 2011 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21840484      PMCID: PMC3157014          DOI: 10.1016/j.ccr.2011.06.016

Source DB:  PubMed          Journal:  Cancer Cell        ISSN: 1535-6108            Impact factor:   31.743


  64 in total

Review 1.  Polycomb group proteins set the stage for early lineage commitment.

Authors:  Lauren E Surface; Seraphim R Thornton; Laurie A Boyer
Journal:  Cell Stem Cell       Date:  2010-09-03       Impact factor: 24.633

2.  ESCs require PRC2 to direct the successful reprogramming of differentiated cells toward pluripotency.

Authors:  Carlos F Pereira; Francesco M Piccolo; Tomomi Tsubouchi; Stephan Sauer; Natalie K Ryan; Ludovica Bruno; David Landeira; Joana Santos; Ana Banito; Jesus Gil; Haruhiko Koseki; Matthias Merkenschlager; Amanda G Fisher
Journal:  Cell Stem Cell       Date:  2010-06-04       Impact factor: 24.633

3.  Phosphorylation of the PRC2 component Ezh2 is cell cycle-regulated and up-regulates its binding to ncRNA.

Authors:  Syuzo Kaneko; Gang Li; Jinsook Son; Chong-Feng Xu; Raphael Margueron; Thomas A Neubert; Danny Reinberg
Journal:  Genes Dev       Date:  2010-12-01       Impact factor: 11.361

4.  MiR-26a inhibits cell growth and tumorigenesis of nasopharyngeal carcinoma through repression of EZH2.

Authors:  Juan Lu; Ming-Liang He; Lu Wang; Ying Chen; Xiong Liu; Qi Dong; Yang-Chao Chen; Ying Peng; Kai-Tai Yao; Hsiang-Fu Kung; Xiang-Ping Li
Journal:  Cancer Res       Date:  2011-01-01       Impact factor: 12.701

5.  Loss of miR-200 inhibition of Suz12 leads to polycomb-mediated repression required for the formation and maintenance of cancer stem cells.

Authors:  Dimitrios Iliopoulos; Marianne Lindahl-Allen; Christos Polytarchou; Heather A Hirsch; Philip N Tsichlis; Kevin Struhl
Journal:  Mol Cell       Date:  2010-09-10       Impact factor: 17.970

Review 6.  Targeting microRNAs in cancer: rationale, strategies and challenges.

Authors:  Ramiro Garzon; Guido Marcucci; Carlo M Croce
Journal:  Nat Rev Drug Discov       Date:  2010-10       Impact factor: 84.694

7.  MicroRNA-101 is down-regulated in gastric cancer and involved in cell migration and invasion.

Authors:  Hui-Ju Wang; Hong-Jun Ruan; Xu-Jun He; Ying-Yu Ma; Xiao-Ting Jiang; Ying-Jie Xia; Zai-Yuan Ye; Hou-Quan Tao
Journal:  Eur J Cancer       Date:  2010-08       Impact factor: 9.162

8.  MicroRNA-101 negatively regulates Ezh2 and its expression is modulated by androgen receptor and HIF-1alpha/HIF-1beta.

Authors:  Paul Cao; Zhiyong Deng; Meimei Wan; Weiwei Huang; Scott D Cramer; Jianfeng Xu; Ming Lei; Guangchao Sui
Journal:  Mol Cancer       Date:  2010-05-17       Impact factor: 27.401

9.  The neuronal repellent SLIT2 is a target for repression by EZH2 in prostate cancer.

Authors:  J Yu; Q Cao; J Yu; L Wu; A Dallol; J Li; G Chen; C Grasso; X Cao; R J Lonigro; S Varambally; R Mehra; N Palanisamy; J Y Wu; F Latif; A M Chinnaiyan
Journal:  Oncogene       Date:  2010-07-12       Impact factor: 9.867

10.  Bmi-1 is a crucial regulator of prostate stem cell self-renewal and malignant transformation.

Authors:  Rita U Lukacs; Sanaz Memarzadeh; Hong Wu; Owen N Witte
Journal:  Cell Stem Cell       Date:  2010-12-03       Impact factor: 24.633

View more
  114 in total

Review 1.  Functional Crosstalk Between Lysine Methyltransferases on Histone Substrates: The Case of G9A/GLP and Polycomb Repressive Complex 2.

Authors:  Chiara Mozzetta; Julien Pontis; Slimane Ait-Si-Ali
Journal:  Antioxid Redox Signal       Date:  2014-12-19       Impact factor: 8.401

Review 2.  Epigenetic regulation of skin: focus on the Polycomb complex.

Authors:  Jisheng Zhang; Evan S Bardot; Elena Ezhkova
Journal:  Cell Mol Life Sci       Date:  2012-07       Impact factor: 9.261

Review 3.  Mechanisms of epigenetic deregulation in lymphoid neoplasms.

Authors:  Yanwen Jiang; Katerina Hatzi; Rita Shaknovich
Journal:  Blood       Date:  2013-05-23       Impact factor: 22.113

4.  KDM5B histone demethylase controls epithelial-mesenchymal transition of cancer cells by regulating the expression of the microRNA-200 family.

Authors:  Zanabazar Enkhbaatar; Minoru Terashima; Dulamsuren Oktyabri; Shoichiro Tange; Akihiko Ishimura; Seiji Yano; Takeshi Suzuki
Journal:  Cell Cycle       Date:  2013-06-06       Impact factor: 4.534

5.  NDY1/KDM2B functions as a master regulator of polycomb complexes and controls self-renewal of breast cancer stem cells.

Authors:  Filippos Kottakis; Parthena Foltopoulou; Ioannis Sanidas; Patricia Keller; Ania Wronski; Benjamin T Dake; Scott A Ezell; Zhu Shen; Stephen P Naber; Philip W Hinds; Elizabeth McNiel; Charlotte Kuperwasser; Philip N Tsichlis
Journal:  Cancer Res       Date:  2014-05-22       Impact factor: 12.701

Review 6.  Maintaining and reprogramming genomic androgen receptor activity in prostate cancer.

Authors:  Ian G Mills
Journal:  Nat Rev Cancer       Date:  2014-03       Impact factor: 60.716

Review 7.  Histone Methyltransferase EZH2: A Therapeutic Target for Ovarian Cancer.

Authors:  Bayley A Jones; Sooryanarayana Varambally; Rebecca C Arend
Journal:  Mol Cancer Ther       Date:  2018-03       Impact factor: 6.261

8.  Myelodysplastic syndromes are induced by histone methylation–altering ASXL1 mutations.

Authors:  Daichi Inoue; Jiro Kitaura; Katsuhiro Togami; Koutarou Nishimura; Yutaka Enomoto; Tomoyuki Uchida; Yuki Kagiyama; Kimihito Cojin Kawabata; Fumio Nakahara; Kumi Izawa; Toshihiko Oki; Akie Maehara; Masamichi Isobe; Akiho Tsuchiya; Yuka Harada; Hironori Harada; Takahiro Ochiya; Hiroyuki Aburatani; Hiroshi Kimura; Felicitas Thol; Michael Heuser; Ross L Levine; Omar Abdel-Wahab; Toshio Kitamura
Journal:  J Clin Invest       Date:  2013-11       Impact factor: 14.808

9.  microRNA-141 regulates BMI1 expression and induces senescence in human diploid fibroblasts.

Authors:  Manjari Dimri; Jeremy D Carroll; Joon-Ho Cho; Goberdhan P Dimri
Journal:  Cell Cycle       Date:  2013-09-24       Impact factor: 4.534

10.  microRNAs and Prostate Cancer.

Authors:  Sajni Josson; Leland W K Chung; Murali Gururajan
Journal:  Adv Exp Med Biol       Date:  2015       Impact factor: 2.622

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.